Hypertension diagnosis (OR 17.71; 95% CI 3.78-129.21) and older age (OR 1.03; 95% CI 1.01-1.05) were associated with higher likelihood of antihypertensive prescribing at discharge after stroke.
Cohort (n=540)
What medical and non-medical factors are associated with antihypertensive prescribing at discharge in patients with stroke or TIA?
In a diverse stroke cohort, older age and Black race were associated with a higher likelihood and number of antihypertensives prescribed at discharge, while insurance status did not explain prescribing differences.
Effect estimate: OR 17.71 (95% CI 3.78-129.21)
Guideline-directed secondary prevention is critical to reduce recurrent stroke and cardiovascular events, including the prescription of antihypertensive medications at discharge for those with Hypertension. However, disparities in Blood Pressure (BP) control after stroke persist. Non-medical factors such as insurance and demographics, and vascular risk may influence prescribing, yet their impact is not well defined. Identifying gaps in care early after stroke can guide interventions to reduce inequities. This study examined medical and non-medical factors associated with antihypertensive prescribing in patients with hypertension during stroke hospitalization. We analyzed 540 patients with ischemic stroke, hemorrhagic stroke, or TIA enrolled in the VIRTUAL trial (March 2022–April 2025). The trial includes patients with prior hypertension or elevated BP during hospitalization in a 6-month telehealth intervention for BP control. Logistic and ordinal regression assessed associations between age, sex, race/ethnicity, insurance, hypertension, and vascular risk factors with (1) any antihypertensive prescription and (2) number of medications. Subgroup analysis was conducted among those with established hypertension. Of 540 patients, 47% were female, median age 63, 22% uninsured, 31.5% Hispanic and 35.4% Non-Hispanic Black, (Table 1). Among patients with hypertension, 87% received ≥1 antihypertensive at discharge. In adjusted analysis, older age (OR 1.03; 95% CI 1.01–1.05) and hypertension diagnosis (OR 17.71; 95% CI 3.78–129.21) were associated with higher prescribing. Among those with hypertension, older age (OR 1.02; 95% CI 1.004–1.03) and Black race (OR 2.00; 95% CI 1.34–2.99) were linked to higher medication counts (Table 2). In this diverse stroke cohort, older age and Black race were linked to both likelihood and number of antihypertensives prescribed, suggesting under-prescribing in younger patients or greater treatment needs in older and Black individuals. Similar patterns observed for Black patients may indicate differences in prescribing or treatment resistance. Insurance status did not explain prescribing differences. Further research is needed to clarify prescribing practices and the trajectory of blood pressure control after stroke.
Flake-Rojas et al. (Wed,) conducted a cohort in Ischemic stroke, hemorrhagic stroke, or TIA (n=540). Medical and non-medical risk factors (older age, hypertension diagnosis, Black race) vs. Younger age, no prior hypertension diagnosis, non-Black race was evaluated on Any antihypertensive prescription at discharge (OR 17.71, 95% CI 3.78-129.21). Hypertension diagnosis (OR 17.71; 95% CI 3.78-129.21) and older age (OR 1.03; 95% CI 1.01-1.05) were associated with higher likelihood of antihypertensive prescribing at discharge after stroke.